US study records decade-long rise in paediatric uveitis

Recorded rates of non-infectious pediatric uveitis increased substantially in the United States between 2016 and 2025, according to a large database study published online ahead of print in the American Journal of Ophthalmology. For opticians, the findings reinforce the value of recognising potentially significant inflammatory signs, taking children’s symptoms seriously and supporting prompt referral when uveitis is suspected.

Researchers analysed de-identified health records from the TriNetX US Collaborative Network, covering 30,729,490 children and adolescents aged 17 years or younger. Among them, 30,533 had a recorded diagnosis of uveitis, equivalent to 0.10% of the population studied. The median age was 11 years, and 54.6% of affected patients were male.

Annual incidence increased from 22 cases per 100,000 children in 2016 to 33 per 100,000 in 2025. The journal abstract reports that prevalence rose from 106 to 226 per 100,000 over the same period. These figures differ from the 199-per-100,000 value reported in some secondary coverage, so the primary publication should be treated as the definitive source.

Anterior disease predominated

Anterior uveitis was by far the most common anatomical subtype, accounting for 22,481 cases, or 73.6% of the cohort. Panuveitis was recorded in 6,841 children, posterior uveitis in 3,468 and intermediate uveitis in 1,527. Although anterior disease was most frequent, the greatest complication burden was not confined to the largest group.

Across the cohort, glaucoma affected 8.8% of children and cataract 6.9%. Blindness or low vision was recorded in 5.2%, macular edema in 3.4% and band keratopathy in 2.2%. Intermediate uveitis carried particularly high rates of glaucoma, cataract and macular edema, at 19.2%, 20.9% and 18.2%, respectively. Posterior uveitis had the highest rate of blindness or low vision, affecting 13.4% of patients in that subgroup.

Juvenile idiopathic arthritis was the leading discrete systemic association, present in 10.4% of children with uveitis. It was most strongly associated with anterior disease. Tubulointerstitial nephritis and uveitis was another notable association, recorded in 1.5% of cases.

Treatment patterns reflected the need for multidisciplinary management. Prednisone was prescribed to 13.6% of patients and methotrexate to 13.1%. Adalimumab, infliximab and mycophenolate were also used. The study describes prescribing patterns rather than recommending treatment, and medication decisions remain the responsibility of the child’s ophthalmology and medical teams.

What this means for opticians

Pediatric uveitis can be difficult to identify because symptoms vary and some children, particularly those with JIA-associated anterior uveitis, may have little or no pain, redness or photophobia. Others may report blurred vision, floaters, light sensitivity or ocular discomfort. A child’s limited ability to describe symptoms can add to the challenge.

Opticians are not expected to diagnose uveitis from symptoms alone, but a careful history and observation can support timely escalation. Practitioners should consider the nature and duration of visual change, unilateral or bilateral involvement, photophobia, pain, redness, floaters and any known inflammatory or autoimmune condition. A previous episode of uveitis, current immunosuppressive treatment or established JIA should heighten awareness.

Where examination reveals reduced visual acuity without a clear explanation, inflammatory signs, abnormal pupils or other concerning findings, referral urgency should reflect the clinical picture and local pathways. Suspected active uveitis warrants prompt assessment by an appropriately equipped eye-care service. Sudden visual loss, severe pain or marked photophobia requires urgent escalation.

Practitioners should also avoid offering reassurance based only on a quiet external appearance. The study’s finding that anterior uveitis predominated is important because inflammation may be present without dramatic visible symptoms. Clear safety-netting is essential: parents and carers should understand which changes require immediate attention and how to access urgent care.

Interpreting the increase

The authors caution that rising recorded rates do not necessarily prove that the underlying disease has become more common. Improved detection, greater awareness, changes in diagnostic coding and expansion of the participating healthcare network may all have influenced the trend. The retrospective analysis relied on coded electronic records and could not examine individual clinical notes, disease severity or the complete clinical course.

Nevertheless, the scale of the dataset provides a useful national view of recorded pediatric uveitis. It also underlines why coordinated care matters: inflammatory eye disease in children may require input from ophthalmology, pediatrics and rheumatology, alongside community eye-care professionals who can identify changes, reinforce follow-up and communicate concerns.

For optical teams, the practical message is straightforward. Pediatric uveitis remains uncommon, but its potential consequences include glaucoma, cataract, macular edema and lasting visual impairment. Careful listening, appropriate examination within professional competence, accurate documentation and timely referral can help children reach specialist care sooner.

As prevalence in recorded data increases, more families may seek advice from community optical practices between specialist appointments. Consistent recall support and rapid communication of new symptoms can strengthen continuity of care.

Reference: Nijim W, Pham NV, Liu R, et al. Incidence, Prevalence, and Clinical Associations of Non-Infectious Pediatric Uveitis in the United States: A TriNetX Database Study. American Journal of Ophthalmology. Published online September 2026. doi: 10.1016/j.ajo.2026.09.025.